Core One Labs Inc.

Core One’s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Read Press Release:

Core One’s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease – Core One Labs Inc. Vancouver, British Columbia, Canada – July 28, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”), is excited to share positive results from its first round of Stage 1 animal model studies (“Round 1”), conducted by its r...